| 1 |
bioRxiv.Severe acute respiratory syndrome-related coronavirus: the species and its viruses - a statement of the coronavirus study group[EB/OL]. (2020-02-11)[2020-06-24].
URL
|
| 2 |
Zhang YZ, Holmes EC.A genomic perspective on the origin and emergence of SARS-CoV-2[J]. Cell, 2020, 181(2): 223-227.
|
| 3 |
Lu R, Zhao X, Li J, et al.Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet, 2020, 395(10224): 565-574.
|
| 4 |
Xu Z, Shi L, Wang Y, et al.Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8(4): 420-422.
|
| 5 |
Hamming I, Timens W, Bulthuis ML, et al.Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus.a first step in understanding SARS pathogenesis[J]. J Pathol, 2004, 203(2): 631-637.
|
| 6 |
Chan JF, Lau SK, To KK, et al.Middle east respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease[J]. Clin Microbiol Rev, 2015, 28(2): 465-522.
|
| 7 |
Cecere TE, Todd SM, Leroith T. Regulatory t cells in arterivirus and coronavirus infections: do they protect against disease or enhance it？[J]. Viruses, 2012, 4(5): 833-846.
|
| 8 |
Qin C, Zhou L, Hu Z, et al.Dysregulation of immune response in patients with COVID-19 in Wuhan, China[J]. Clin Infect Dis, 2020, 71(15): 762-768.
|
| 9 |
姚小红，李廷源，何志承，等．新型冠状病毒肺炎(COVID-19)三例遗体多部位穿刺组织病理学研究[J]．中华病理学杂志，2020，49(5)：411-417.
|
| 10 |
Liu J, Li S, Liu J, et al.Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-Co V-2 infected patients[J]. EBio Med, 2020(55): 102763.
|
| 11 |
Huang C, Wang Y, Li X, et al.Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.
|
| 12 |
Wang D, Hu B, Hu C, et al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020, 323(11): 1061-1069.
|
| 13 |
Chen N, Zhou M, Dong X, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513.
|
| 14 |
medRxiv.Clinical characteristics of 2019 novel coronavirus infection in China[EB/OL]. (2020-02-09)[2020-06-24].
URL
|
| 15 |
国家卫生健康委员会办公厅．国家中医药管理局办公室．关于印发新型冠状病毒肺炎诊疗方案(试行第五版)的通知[EB/OL]．(2020-02-05)[2020-06-24]．
URL
|
| 16 |
国家卫生健康委员会办公厅．国家中医药管理局办公室．关于印发新型冠状病毒肺炎诊疗方案(试行第六版)的通知[EB/OL]．(2020-02-18)[2020-06-24]．
URL
|
| 17 |
bioRxiv.Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin[EB/OL]. (2020-01-23)[2020-06-24].
URL
|
| 18 |
Cinatl J Jr, Michaelis M, Hoever G, et al.Development of antiviral therapy for severe acute respiratory syndrome[J]. Antiviral Res, 2005, 66(2-3): 81-97.
|
| 19 |
De Clercq E, Cools M, Balzarini J, et al.Antiviral activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide and related compounds[J]. Antimicrob Agents Chemother, 1991, 35(4): 679-684.
|
| 20 |
van Griensven J, Edwards T, de Lamballerie X, et al.Evaluation of convalescent plasma for ebola virus disease in guinea[J]. N Engl J Med, 2016, 374(1): 33-42.
|
| 21 |
Cinatl J Jr, Michaelis M, Morgenstern B, et al.High-dose hydrocortisone reduces expression of the pro-inflammatory chemokines CXCL8 and CXCL10 in SARS coronavirus-infected intestinal cells[J]. Int J Mol Med, 2005, 15(2): 323-327.
|
| 22 |
Zhang XW, Yap YL.Old drugs as lead compounds for a new disease? binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs[J]. Bioorg Med Chem, 2004, 12(10): 2517-2521.
|
| 23 |
Chan KS, Lai ST, Chu CM, et al.Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study[J]. Hong Kong Med J, 2003, 9(6): 399-406.
|
| 24 |
Yamamoto N, Yang R, Yoshinaka Y, et al.HIV protease inhibitor nel？navir inhibits replication of SARS-associated coronavirus[J]. Biochem Biophys Res Commun, 2004, 318(3): 719-25.
|
| 25 |
Chu CM, Cheng VC, Hung IF, et al.Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings[J]. Thorax, 2004, 59(3): 252-256.
|
| 26 |
Lane TE, Paoletti AD, Buchmeier MJ.Disassociation between the in vitro and in vivo effects of nitric oxide on a neurotropic murine coronavirus[J]. J Virol, 1997, 71(3): 2202-2210.
|
| 27 |
Keyaerts E, Vijgen L, Maes P, et al.In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine[J]. Biochem Biophys Res Commun, 2004, 323(1): 264-268.
|
| 28 |
Chen L, Liu P, Gao H, et al.Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing[J]. Clin Infect Dis, 2004, 39(10): 1531-1535.
|
| 29 |
Towler P, Staker B, Prasad SG, et al.ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis[J]. J Biol Chem, 2004, 279(17): 17996-8007.
|
| 30 |
Chan JF, Yao Y, Yeung ML, et al.Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset[J]. J Infect Dis, 2015, 212(12): 1904-1913.
|
| 31 |
Omrani AS, Saad MM, Baig K, et al.Ribavirin and interferon Alfa-2a for severe middle east respiratory syndrome coronavirus infection: a retrospective cohort study[J]. Lancet Infect Dis, 2014, 14(11): 1090-1095.
|
| 32 |
Momattin H, Al-Ali AY, Al-Tawfiq JA.A systematic review of therapeutic agents for the treatment of the middle east respiratory syndrome coronavirus (MERS-CoV)[J]. Travel Med Infect Dis, 2019(30): 9-18.
|
| 33 |
Wang M, Cao R, Zhang L, et al.Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro[J]. Cell Res, 2020 , 30(3): 269-271.
|
| 34 |
Paules CI, Marston HD, Fauci AS.Coronavirus infections—more than just the common cold[J]. JAMA, 2020, 323(8): 707-708.
|
| 35 |
Falzarano D, de Wit E, Rasmussen AL, et al.Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques[J]. Nat Med, 2013, 19(10): 1313-1317.
|
| 36 |
Leneva IA, Falynskova IN, Makhmudova NR, et al.Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study[J]. J Med Virol, 2019, 91(4): 588-597.
|
| 37 |
SSRN.Clinical efficacy of arbidol in patients with 2019 novel coronavirusinfected pneumonia: a retrospective cohort study[EB/OL]. (2020-02-25)[2020-06-24].
URL
|
| 38 |
国家卫生健康委员会办公厅．国家中医药管理局办公室．新型冠状病毒感染的肺炎诊疗方案(试行第八版)[EB/OL]．(2020-08-18)[2020-06-24]．
URL
|
| 39 |
Gallagher TM, Buchmeier MJ.Coronavirus spike proteins in viral entry and pathogenesis[J]. Virology, 2001, 279(2): 371-374.
|
| 40 |
bioRxiv.The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes[EB/OL]. (2020-01-31)[2020-06-24].
URL
|
| 41 |
Wang P, Chen J, Zheng A, et al.Expression cloning of functional receptor used by SARS coronavirus[J]. Biochem Biophys Res Commun, 2004, 315(2): 439-444.
|
| 42 |
bioRxiv.Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig[EB/OL]. (2020-02-02)[2020-06-24].
URL
|
| 43 |
Richardson P, Griffin I, Tucker C, et al.Baricitinib as potential treatment for 2019-nCoV acute respiratory disease[J]. Lancet, 2020, 395(10223): e30-e31.
|
| 44 |
Wu J, Zhou L, Liu J, Ma G, et al.The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial[J]. Crit Care, 2013, 17(1): R8.
|
| 45 |
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al.The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis[J]. J Infect Dis, 2015, 211(1): 80-90.
|
| 46 |
中国研究型医院学会危重医学专业委员会，中国研究型医院学会危重医学专委会青年委员会．重型和危重型新型冠状病毒肺炎诊断和治疗专家共识(修订版)[J/OL]．中华危重病急救医学，2020，32(3)：269-274.
|
| 47 |
Shao Z, Feng Y, Zhong L, et al.Clinical efficacy of intravenous immunoglobulin therapy in critical patients with COVID-19: Amulticenter retrospective cohort study[J]. Clin Transl Immunology, 2020, 9(10): e1192.
|
| 48 |
Yokota S, Miyamae T, Imagawa T, et al.Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis[J]. Arthritis Rheum, 2005, 52(3): 818-825.
|
| 49 |
RECOVERY Collaborative Group, Horby P, Lim WS, et al.Dexamethasone in hospitalized patients with COVID-19[J]. N Engl J Med, 2021, 384(8): 693-704.
|
| 50 |
Stone JH, Frigault MJ, Serling-Boyd NJ, et al.Efficacy of tocilizumab in patients hospitalized with COVID-19[J]. N Engl J Med, 2020, 383(24): 2333-2344.
|
| 51 |
Wan YD, Sun TW, Liu ZQ, et al.Efficacy and safety of corticosteroids for community-acquired pneumonia: a systematic review and meta-analysis[J]. Chest, 2016, 149(1): 209-219.
|
| 52 |
Arabi YM, Mandourah Y, Al-Hameed F, et al.Corticosteroid therapy for critically ill patients with middle east respiratory syndrome[J]. Am J Respir Crit Care Med, 2018, 197(6): 757-767.
|
| 53 |
Ni YN, Chen G, Sun J, et al.The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis[J]. Crit Care, 2019, 23(1): 99.
|
| 54 |
Russell CD, Millar JE, Baillie JK.Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J]. Lancet, 2020, 395(10223): 473-475.
|
| 55 |
WHO.Global surveillance for human infection with novel coronavirus(2019-nCoV)[EB/OL]. (2020-01-31)[2020-06-24].
URL
|
| 56 |
McIntyre LA, Stewart DJ, Mei SHJ, et al.Cellular immunotherapy for septic shock.a phase i clinical trial[J]. Am J Respir Crit Care Med, 2018, 197(3): 337-347.
|
| 57 |
He X, Ai S, Guo W, et al.Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: aphase 1 clinical trial[J]. Transl Res, 2018(199): 52-61.
|
| 58 |
Marik PE, Khangoora V, Rivera R, et al.Hydrocortisone Vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study[J]. Chest, 2017, 151(6): 1229-1238.
|
| 59 |
Wald EL, Sanchez-Pinto LN, Smith CM, et al.Hydrocortisone-ascorbic acid-thiamine use associated with lower mortality in pediatric septic shock[J]. Am J Respir Crit Care Med, 2020, 201(7): 863-867.
|
| 60 |
Fowler AA 3rd, Syed AA, Knowlson S, et al.Phase i safety trial of intravenous ascorbic acid in patients with severe sepsis[J]. J Transl Med, 2014(12): 32.
|
| 61 |
Donnino MW, Andersen LW, Chase M, et al.Randomized, double-blind, placebo-controlled trial of thiamine as a metabolic resuscitator in septic shock: a pilot study[J]. Crit Care Med, 2016, 44(2): 360-7.
|
| 62 |
脓毒症免疫调理治疗临床研究协作组．乌司他丁、α1胸腺肽联合治疗严重脓毒症——一种新的免疫调理治疗方法的临床研究[J]．中华医学杂志，2007，87(7)：451-457.
|
| 63 |
Karnad DR, Bhadade R, Verma PK, et al.Intravenous administration of ulinastatin (human urinary trypsin inhibitor)in severe sepsis：a multicenter randomized controlled study[J]．Intensive Care Med，2014，40(6)：830-838.
|
| 64 |
Jin Y, Yang H, Ji W, et al.Virology, epidemiology, pathogenesis, and control of COVID-19[J]. Viruses, 2020, 12(4): 372.
|
| 65 |
顾觉奋．新型冠状病毒肺炎临床治疗药物最新研究进展[J]．中国新药杂志，2021，30(2)：154-161.
|
| 66 |
吴昊，王佳琪，杨雨薇，等．基于网络药理学和分子对接技术初步探索"清肺排毒汤"抗新型冠状病毒肺炎作用机制[J]．药学学报，2020，55(3)：374-383.
|
| 67 |
Hu K, Guan WJ, Bi Y, et al.Efficacy and safety of lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial[J]. Phytomedicine, 2021(85): 153242.
|